A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days (Q40731233)
Jump to navigation
Jump to search
scientific article published on August 1, 1992
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days |
scientific article published on August 1, 1992 |
Statements
1 reference
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days (English)
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days (English)
Burris HA 3rd
1 reference
Kneuper-Hall R
1 reference
O'Rourke T
1 reference
J. G. Wall
H. A. Burris
D. D. Von Hoff
G. Rodriguez
R. Kneuper-Hall
D. Shaffer
T. O'Rourke
T. Brown
G. Weiss
1 August 1992
1 reference
1 reference